Mylan completes acquisition of Jai Pharma
Mylan Laboratories Limited, a subsidiary of Nasdaq-listed Mylan NV, on Friday said it successfully completed the acquisition of certain women’s healthcare businesses - known as Jai Pharma - which were hived off from Famy Care Limited. However, it did not disclose financial details of the acquisition.
Hyderabad: Mylan Laboratories Limited, a subsidiary of Nasdaq-listed Mylan NV, on Friday said it successfully completed the acquisition of certain women’s healthcare businesses - known as Jai Pharma - which were hived off from Famy Care Limited. However, it did not disclose financial details of the acquisition.
The transaction brings Mylan a broad women’s care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's global commercial footprint and supply chain infrastructure, will create a leading women’s healthcare franchise.
"The completion of this transaction is an important milestone as we continue to grow our global women’s healthcare franchise, and take another step in our mission to provide the world’s 7 billion people access to high quality medicine,” said Mylan CEO Heather Bresch. In addition to strengthening our women’s healthcare offering in North America, we will continue to leverage our powerful commercial platform in Europe, now enhanced through our recent Abbott deal, to serve this important therapeutic area, he added.
